Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evolus Inc EOLS

Healthcare
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar... see more

Recent & Breaking News (NDAQ:EOLS)

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Business Wire March 8, 2023

Evolus to Participate in the Barclays Global Healthcare Conference

Business Wire February 28, 2023

Evolus Initiates Nuceiva® Launch in Germany and Austria

Business Wire February 27, 2023

Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update

Business Wire February 22, 2023

Evolus Not Affected by Recent Korean Court Ruling

Business Wire February 10, 2023

Evolus to Participate in the SVB Securities Global Biopharma Conference

Business Wire January 31, 2023

"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance

Business Wire January 28, 2023

Evolus Receives Regulatory Approval for Nuceiva® in Australia

Business Wire January 23, 2023

Evolus to Present Phase 2 Interim Data from Jeuveau® "Extra-Strength" Dose for Extended Duration Study at 2023 IMCAS World Congress

Business Wire January 23, 2023

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration

Business Wire January 18, 2023

Evolus Extends Term of Credit Facility with Pharmakon Advisors

Business Wire December 8, 2022

Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc.

PR Newswire December 7, 2022

Evolus Reports Third Quarter 2022 Results and Provides Business Update

Business Wire November 8, 2022

Evolus to Participate in November Conferences

Business Wire November 2, 2022

Evolus to Report Third Quarter 2022 Results and Provide Business Update

Business Wire October 25, 2022

Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

Business Wire October 4, 2022

Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022

Business Wire September 21, 2022

Evolus Announces Inducement Grants for New Chief Financial Officer

Business Wire September 6, 2022

Evolus Appoints Sandra Beaver as Chief Financial Officer

Business Wire August 30, 2022

Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Business Wire August 29, 2022